Equillium is a La Jolla biotechnology company developing treatments for autoimmune and inflammatory diseases, starting with ulcerative colitis. EQ reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 4 | Roth Capital | Reiterated | Buy | |
| Jul 13 | Piper Sandler | Initiated | Buy | |
| May 28 | Leerink Partners | Upgrade | Buy | |
| Apr 16 | B. Riley Securities | Initiated | Buy | |
| Apr 14 | Raymond James | Initiated | Buy |
Seasonality
How EQ has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in EQ in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EQ is in one of them and how their past EQ trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered EQ in an article yet. Here's the latest on the wider market.
About Equillium
Equillium is a biotechnology company in La Jolla, California, that develops treatments for severe autoimmune and inflammatory diseases. Its lead candidate, EQ504, works on the aryl hydrocarbon receptor and is being developed first for ulcerative colitis and other gut diseases. The company also has an oral candidate, EQ302, that blocks two inflammatory signaling proteins and is aimed at celiac disease. Both candidates are still in development and not yet sold, with patients who have gut and immune disorders as the intended users.
- Headquarters
- La Jolla, CA